Field study to investigate the effectiveness and safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio® Plus) against natural flea and tick infestations on dogs presented as veterinary patients in Europe

Table 6 Effectiveness of three consecutive monthly doses of Credelio Plus^® and afoxolaner + milbemycin oxime based on laboratory counts and speciation of natural Ixodes ricinus and R. sanguineus (s.l.) tick infestations on client owned dogs in European field study

Study day	Treatment group	I. ricinus		R. sanguineus
Study day	Treatment group	AM tick count	% Effectiveness	AM tick count	% Effectiveness
0	Credelio Plus^®	4.6	–	5.9	–
	Afoxolaner + Milbemycin oxime	4.2	–	5.6	–
7 ± 2	Credelio Plus^®	0.28	93.9	0.34	94.2
	Afoxolaner + Milbemycin oxime	0.26	93.8	0	100
14 ± 2	Credelio Plus®	0.04	99.1	0	100
	Afoxolaner + Milbemycin oxime	0.04	99.0	0.32	94.3
21 ± 2	Credelio Plus^®	0.05	98.9	0.09	98.5
	Afoxolaner + Milbemycin oxime	0.06	98.6	0.16	97.1
28 ± 2	Credelio Plus^®	0.06	98.7	0	100
	Afoxolaner + Milbemycin oxime	0.04	99.0	0	100
42 ± 2	Credelio Plus^®	0.02	99.6	0	100
	Afoxolaner + Milbemycin oxime	0	100	0.16	97.1
56 ± 2	Credelio Plus^®	0.07	98.5	0	100
	Afoxolaner + Milbemycin oxime	0	100	0	100
70 ± 2	Credelio Plus^®	0	100	0	100
	Afoxolaner + Milbemycin oxime	0.02	99.5	0	100
84 ± 2	Credelio Plus^®	0.03	99.3	0	100
	Afoxolaner + Milbemycin oxime	0.10	99.8	0	100

Before treatment administration on Day 0, the number of dogs in the Credelio Plus^® and afoxolaner + milbemycin oxime groups infested with each species was 94 and 48 for I. ricinus and 32 and 19 for R. sanguineus, respectively

ISSN: 1756-3305